This website tells you more about Creon and
Pancreatic Exocrine Insufficiency
Mylan, the marketing authorisation holder for Creon in the UK, has been experiencing a constraint in the supply of Creon 25K.
Stock levels have begun to resume, and we are beginning to see improvement in patient’s ability to readily access Creon 25K. We expect this to further improve and we will continue to keep www.creon.co.uk updated with the latest supply information.
Due to the supply constraints of Creon 25K, there has been increasing demand for Creon 10K. Currently availability of supplies in the UK will vary from pharmacy to pharmacy and as such some areas may experience supply issues with Creon 10K until the end of June.
With patient access as our priority, we will continue to proactively update pharmacies, healthcare professionals and patient advocacy groups across the country regarding any changes in stock availability.
At this time, there is currently no supply constraints of Creon Micro.
Mylan has decided to voluntarily discontinue Creon 40K from June 2019. This decision is not associated with any safety or efficacy findings.
Compared to all other doses, producing Creon 40K requires a different concentration of active enzymes which have been decreasing over the last few years and because of this Creon 40K has experienced frequent supply constraints.
Creon capsules are interchangeable, and patients can achieve the higher dose by taking more of the lower strength capsules. Patients should not be concerned about the efficacy when switching to a lower strength capsule.
Mylan is unable to make any specific treatment recommendations to healthcare professionals or for individual patients, however, it is recommended that patients affected by this should speak to their treating physician to discuss treatment options according to their health needs and their relevant clinical history.
Creon is a Pancreatic Enzyme Replacement Therapy (PERT) that helps patients with Pancreatic Exocrine Insufficiency (PEI) to break down food and digest nutrients by replacing the pancreatic enzymes made by a healthy pancreas. The active substance of Creon is pancreatin, a natural substance from the pancreas of the pig; as a biologic product Creon is produced using a complex manufacturing process that is subject to high standards and strict requirements in terms of quality and compliance.
If you require additional information or have any questions, please contact +44(0) 1707 853 100.
Please select from below depending on whether you are
a Creon patient, or a UK Healthcare Professional
This website is intended for use by UK Healthcare Professionals and patients who have been prescribed Creon